Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
Qiming Venture Partners
AddedJul 2, 2026
UpdatedJul 2, 2026
Qiming Venture Partners

Qiming Venture Partners

Operating

Qiming Venture Partners is a venture capital firm backing technology and healthcare companies.

Location
Shanghai, Shanghai, CN
Founded
2006
Committed Capital Total
$9.5B
Geographic Focus
regional
Firm
Analysis
Compare
Portfolio
Employees
News
Website

Investments

LongBio Pharma
LongBio Pharma
Series C

Total Raised

$300M

Rounds

2

Series C$200MJune 2025
Series B$100MSeptember 2024
Axera Technology
Axera Technology
Public

Total Raised

$1.9B

Rounds

3

Series C$1BApril 2025
Series A$800MJanuary 2022
Seed$100MApril 2020
Alamar Biosciences
Alamar Biosciences
Series C

Total Raised

$222M

Rounds

3

Series C$128MFebruary 2024
Series B$80MSeptember 2021
Series A$14MMay 2020
Viewtrix Technology
Viewtrix Technology
Acquisition

Rounds

3

Series DJanuary 2024
Ailomics Therapeutics
Ailomics Therapeutics
Seed

Total Raised

$38.6M

Rounds

2

Seed$8.6MMay 2023
Angel$30MSeptember 2022
Allorion Therapeutics
Allorion Therapeutics

Total Raised

$90M

Rounds

3

Series B$50MMarch 2023
Series A$40MNovember 2021
Aistarfish Healthcare
Aistarfish Healthcare
Series B

Total Raised

$400M

Rounds

2

Series B$200MMay 2022
Series B$200MFebruary 2022
Ark Biosciences
Ark Biosciences
Series D

Total Raised

$170M

Rounds

4

Series D$80MJanuary 2022
Series C$50MJanuary 2021
Abogen Biosciences
Abogen Biosciences
Series C

Total Raised

$1B

Rounds

2

Series C$300MNovember 2021
Series C$700MAugust 2021
Aohua Endoscopy
Aohua Endoscopy
Public

Total Raised

$191.2M

Rounds

3

IPO$117.5MNovember 2021
APT Medical
APT Medical
Public

Total Raised

$1.2B

Rounds

1

IPO$1.2BJanuary 2021
Antengene
Antengene
Public

Total Raised

$3B

Rounds

4

IPO$2.8BNovember 2020
Series C$97MJuly 2020
Asieris Pharmaceuticals
Asieris Pharmaceuticals
Series D

Total Raised

$498M

Rounds

2

Series D$108MNovember 2020
Apollomics
Apollomics
Series C

Total Raised

$244.2M

Rounds

4

Series C$124.2MNovember 2020